Management of Patients with Chronic Heart Failure and Diabetes Mellitus

Chronic heart failure (CHF) occurs in 4.3-28% of patients with diabetes mellitus and is most often associated with the presence of coronary heart disease, arterial hypertension and the direct adverse effects of insulin-resistance, hyperinsulinemia and hyperglycemia on the myocardium. Diabetes mellit...

Full description

Bibliographic Details
Main Authors: E. V. Reznik, T. L. Nguyen, G. N. Golukhov
Format: Article
Language:English
Published: Столичная издательская компания 2021-05-01
Series:Рациональная фармакотерапия в кардиологии
Subjects:
Online Access:https://www.rpcardio.online/jour/article/view/2445
_version_ 1797232119225778176
author E. V. Reznik
T. L. Nguyen
G. N. Golukhov
author_facet E. V. Reznik
T. L. Nguyen
G. N. Golukhov
author_sort E. V. Reznik
collection DOAJ
description Chronic heart failure (CHF) occurs in 4.3-28% of patients with diabetes mellitus and is most often associated with the presence of coronary heart disease, arterial hypertension and the direct adverse effects of insulin-resistance, hyperinsulinemia and hyperglycemia on the myocardium. Diabetes mellitus occurs in 12-47% of patients with CHF and can develop within several years after a diagnosis of HF in 22% of patients due to insulin-resistance of failure tissues. The presence of diabetes mellitus leads to a greater severity of clinical symptoms and hospitalization rate, worsening of quality of life and prognosis in CHF. A decreased left ventricular ejection fraction is an independent predictor of the poor prognosis in the patients with diabetes mellitus. The algorithm of the treatment of CHF in the patients with and without diabetes mellitus is not fundamentally different, but it requires taking into account the metabolic effects of the prescribed drugs. Angiotensin receptor-neprilysin inhibitor are increasingly used in clinical practice and are gradually replacing angiotensin-converting enzyme inhibitors and sartans in CHF both without diabetes mellitus and in its presence. Recently, the effectiveness of type 2 sodium glucose cotransporter inhibitors has been proven in patients with CHF with and without diabetes mellitus. This review is devoted to the relationship of diabetes mellitus and CHF, as well as the approaches to the management of such comorbid patients.
first_indexed 2024-03-08T14:01:31Z
format Article
id doaj.art-da3c5fa07922424e99f4f5872610d865
institution Directory Open Access Journal
issn 1819-6446
2225-3653
language English
last_indexed 2024-04-24T15:55:12Z
publishDate 2021-05-01
publisher Столичная издательская компания
record_format Article
series Рациональная фармакотерапия в кардиологии
spelling doaj.art-da3c5fa07922424e99f4f5872610d8652024-04-01T07:43:41ZengСтоличная издательская компанияРациональная фармакотерапия в кардиологии1819-64462225-36532021-05-0117234135010.20996/1819-6446-2021-04-051884Management of Patients with Chronic Heart Failure and Diabetes MellitusE. V. Reznik0T. L. Nguyen1G. N. Golukhov2Russian National Research Medical University n.a. N.I. Pirogov; City Clinical Hospital n.a. V.M. Buyanov; City Clinical Hospital №31Russian National Research Medical University n.a. N.I. PirogovCity Clinical Hospital №31Chronic heart failure (CHF) occurs in 4.3-28% of patients with diabetes mellitus and is most often associated with the presence of coronary heart disease, arterial hypertension and the direct adverse effects of insulin-resistance, hyperinsulinemia and hyperglycemia on the myocardium. Diabetes mellitus occurs in 12-47% of patients with CHF and can develop within several years after a diagnosis of HF in 22% of patients due to insulin-resistance of failure tissues. The presence of diabetes mellitus leads to a greater severity of clinical symptoms and hospitalization rate, worsening of quality of life and prognosis in CHF. A decreased left ventricular ejection fraction is an independent predictor of the poor prognosis in the patients with diabetes mellitus. The algorithm of the treatment of CHF in the patients with and without diabetes mellitus is not fundamentally different, but it requires taking into account the metabolic effects of the prescribed drugs. Angiotensin receptor-neprilysin inhibitor are increasingly used in clinical practice and are gradually replacing angiotensin-converting enzyme inhibitors and sartans in CHF both without diabetes mellitus and in its presence. Recently, the effectiveness of type 2 sodium glucose cotransporter inhibitors has been proven in patients with CHF with and without diabetes mellitus. This review is devoted to the relationship of diabetes mellitus and CHF, as well as the approaches to the management of such comorbid patients.https://www.rpcardio.online/jour/article/view/2445chronic heart failurediabetes mellitusleft ventricular ejection fractionpharmacotherapyangiotensin receptor-neprilysin inhibitorsglt-2sodium-glucose cotransporter-2
spellingShingle E. V. Reznik
T. L. Nguyen
G. N. Golukhov
Management of Patients with Chronic Heart Failure and Diabetes Mellitus
Рациональная фармакотерапия в кардиологии
chronic heart failure
diabetes mellitus
left ventricular ejection fraction
pharmacotherapy
angiotensin receptor-neprilysin inhibitor
sglt-2
sodium-glucose cotransporter-2
title Management of Patients with Chronic Heart Failure and Diabetes Mellitus
title_full Management of Patients with Chronic Heart Failure and Diabetes Mellitus
title_fullStr Management of Patients with Chronic Heart Failure and Diabetes Mellitus
title_full_unstemmed Management of Patients with Chronic Heart Failure and Diabetes Mellitus
title_short Management of Patients with Chronic Heart Failure and Diabetes Mellitus
title_sort management of patients with chronic heart failure and diabetes mellitus
topic chronic heart failure
diabetes mellitus
left ventricular ejection fraction
pharmacotherapy
angiotensin receptor-neprilysin inhibitor
sglt-2
sodium-glucose cotransporter-2
url https://www.rpcardio.online/jour/article/view/2445
work_keys_str_mv AT evreznik managementofpatientswithchronicheartfailureanddiabetesmellitus
AT tlnguyen managementofpatientswithchronicheartfailureanddiabetesmellitus
AT gngolukhov managementofpatientswithchronicheartfailureanddiabetesmellitus